Canopus BioPharma Strengthens Its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement wit

  
    
  
  
    
      Canopus BioPharma, Inc. (OTC: CBIA), a biotechnology company developing 
      pharmaceutical products and assay methods for patients suffering from 
      infectious disease, radiation sickness, cancer and addiction, today 
      announced the signing of a licensing agreement with the Wisconsin Alumni 
      Research Foundation (WARF), an organization serving the University of 
      Wisconsin-Madison scientific community by patenting the discoveries of 
      UW-Madison researchers and licensing these technologies to leading 
      companies in Wisconsin, the United States and worldwide. The agreement 
      provides comprehensive licensing rights and patent protection relating 
      to Canopus’ Phase II oncology drug candidate, 
      CB1400.
    
    
      “Securing the rights to the WARF patents 
      strengthens Canopus BioPharma’s intellectual 
      property position for future licensing opportunities of CB1400, one of 
      our most exciting products,” said Patrick 
      Prendergast, Chairman and Chief Executive Officer of Canopus BioPharma. “In 
      the near future, we expect to announce important results from our 
      studies using CB1400, which will further validate the potential 
      significance of our drug for oncology and related indications.”
    
    
      Canopus BioPharma expects to develop CB1400 as a method for preventing 
      and reducing mucositis (lesions in the gastrointestinal and oral mucosa 
      caused by chemo- and/or radiotherapy). The domestic market alone for a 
      preventative anti-mucositis agent is estimated to be over $1 billion per 
      annum. The compound underlying CB1400 had been previously developed and 
      patented by a major pharmaceutical company as an anti-parasitic agent. 
      Canopus discovered that this approved drug was highly effective for an 
      alternative indication, specifically for use in preventing mucositis. 
      Canopus BioPharma’s market opportunity with 
      CB1400 includes various applications associated with cancer therapy and 
      cancer treatment side effects.
    
    
      CB1400, a former anti-schistosomal drug, is currently in phase II 
      clinical development by Canopus as an anti-mucositis preventative agent 
      in patients receiving radio- and/or chemotherapy treatment. CB1400 alone 
      and in combination with both cisplatin and cetuximab (Erbitux), has also 
      been shown to inhibit tumor growth in two mice models of lung cancer, 
      thus demonstrating the broad capabilities of this compound in the 
      treatment of cancer.
    
    
      About the Wisconsin Alumni Research Foundation:
    
    
      The Wisconsin Alumni Research Foundation (WARF) supports research at the 
      University of Wisconsin-Madison by protecting the intellectual property 
      of University faculty, staff and students, and licensing inventions 
      resulting from their work. Through these efforts, university ideas 
      benefit the public by bringing resources back to the university to 
      continue the cycle of investment, research and invention. WARF (www.warf.org) 
      was established in 1925 as the first university-based technology 
      transfer office in the world.
    
    
      About Canopus BioPharma, Inc.:
    
    
      Canopus BioPharma, Inc. (OTC: CBIA) is dedicated to providing the 
      safest, most cost effective and efficacious pharmaceutical products and 
      assay methods in the areas of infectious disease, radiation protection, 
      cancer, and addiction. With innovative science, proven research and 
      development leadership, and superior products and compounds, Canopus 
      BioPharma has, since 2001, been committed to becoming a market trend 
      setter in a new era of healthcare. In addition, the Company is a world 
      leader in the development of novel camelid antibody products to provide 
      unique avenues of progress and improvement in assay methods and 
      monitoring capabilities for physicians, patients and researchers, 
      initially for food chain protection applications. Canopus maintains 
      staff in Australia, South Africa, Ireland, Panama and the USA. 
      Additional information on the Company is available at www.canopusbiopharma.com.